TY - JOUR
T1 - Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis
T2 - An international audit
AU - Semb, Anne Grete
AU - Rollefstad, Silvia
AU - Ikdahl, Eirik
AU - Wibetoe, Grunde
AU - Sexton, Joseph
AU - Crowson, Cindy
AU - Van Riel, Piet
AU - Kitas, George
AU - Graham, Ian
AU - Rantapää-Dahlqvist, Solbritt
AU - Karpouzas, George Athanasios
AU - Myasoedova, Elena
AU - Gonzalez-Gay, Miguel A.
AU - Sfikakis, Petros P.
AU - Tektonidou, Maria G.G.
AU - Lazarini, Argyro
AU - Vassilopoulos, Dimitrios
AU - Kuriya, Bindee
AU - Hitchon, Carol
AU - Stoenoiu, Maria Simona
AU - Durez, Patrick
AU - Pascual-Ramos, Virginia
AU - Galarza-Delgado, Dionicio Angel
AU - Faggiano, Pompilio
AU - Misra, Durga Prasanna
AU - Borg, Andrew A.
AU - Mu, Rong
AU - Mirrakhimov, Erkin M.
AU - Gheta, Diane
AU - Douglas, Karen
AU - Agarwal, Vikas
AU - Myasoedova, Svetlana
AU - Krougly, Lev
AU - Valentinovna Popkova, Tatiana
AU - TuchyÅ ová, Alena
AU - Tomcik, Michal
AU - Vrablik, Michal
AU - Lastuvka, Jiri
AU - Horak, Pavel
AU - Medkova, Helena Kaspar
AU - Kerola, Anne M.
N1 - Publisher Copyright:
©
PY - 2021/7/8
Y1 - 2021/7/8
N2 - Aim The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. Methods The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014-2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. Results The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p<0.001). The proportion of patients with a diagnosis of hypertension, hyperlipidaemia and use of lipid-lowering or antihypertensive agents was higher among RA-DM than RAwoDM (p<0.001 for all). The majority of patients with ASCVD did not reach the lipid goal of low-density lipoprotein cholesterol <1.8 mmol/L. The lipid goal attainment was statistically and clinically significantly higher in RA-DM compared with RAwoDM both for patients with and without ASCVD. The systolic BP target of <140 mm Hg was reached by the majority of patients, and there were no statistically nor clinically significant differences in attainment of BP targets between RA-DM and RAwoDM. Conclusion CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA.
AB - Aim The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. Methods The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014-2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. Results The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p<0.001). The proportion of patients with a diagnosis of hypertension, hyperlipidaemia and use of lipid-lowering or antihypertensive agents was higher among RA-DM than RAwoDM (p<0.001 for all). The majority of patients with ASCVD did not reach the lipid goal of low-density lipoprotein cholesterol <1.8 mmol/L. The lipid goal attainment was statistically and clinically significantly higher in RA-DM compared with RAwoDM both for patients with and without ASCVD. The systolic BP target of <140 mm Hg was reached by the majority of patients, and there were no statistically nor clinically significant differences in attainment of BP targets between RA-DM and RAwoDM. Conclusion CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA.
KW - arthritis
KW - atherosclerosis
KW - cardiovascular diseases
KW - hypertension
KW - lipids
KW - rheumatoid
UR - http://www.scopus.com/inward/record.url?scp=85109542579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109542579&partnerID=8YFLogxK
U2 - 10.1136/rmdopen-2021-001724
DO - 10.1136/rmdopen-2021-001724
M3 - Article
C2 - 34244381
AN - SCOPUS:85109542579
SN - 2056-5933
VL - 7
JO - RMD Open
JF - RMD Open
IS - 2
M1 - e001724
ER -